CJC-1295
Also searched as: Modified GRF (1-29) · CJC-1295 DAC · Mod GRF 1-29
CJC-1295 is a synthetic analogue of growth hormone releasing hormone, modified to resist enzymatic breakdown. It exists in two forms that are routinely confused: with DAC (drug affinity complex), which binds albumin and has a much longer half-life, and without DAC, often labelled Modified GRF (1-29), which does not. The two behave very differently.
What the research has looked at
- Growth hormone and IGF-1 levels in early human studies
- Half-life extension via albumin binding
- Pulsatile versus sustained growth hormone release patterns
This is a description of what has been studied, not a claim about what it does. Evidence level: early human data.
Legal position in the UK
Not a licensed medicine in the UKNot licensed as a medicine in the UK. Prohibited in sport at all times under WADA class S2.
Handling and storage
Lyophilised powder. Which version you have changes nothing about reconstitution but everything about the arithmetic, because vial sizes differ between the DAC and non-DAC forms.
Vial sizes: Commonly 2mg or 5mg per vial. Where a manufacturer supplies handling instructions, those take precedence over anything general.
Questions
- What is the difference between CJC-1295 with and without DAC?
- DAC is a chemical group that binds to albumin in the blood, extending the half-life from minutes to days. Without DAC, the molecule is essentially Modified GRF (1-29) and clears quickly. Supplier listings often use the names loosely, so the label is worth checking carefully.
- Is CJC-1295 the same as Tesamorelin?
- No, though both are GHRH analogues. Tesamorelin is an approved medicine in some jurisdictions for a specific indication. CJC-1295 is not approved anywhere.